Delineation of an epitope recognized by a chikungunya virus anti-capsid monoclonal antibody on the protease domain using an immuno-informatics approach

Author(s):  
Aabha Thite ◽  
Megha Agrawal ◽  
Daya Pavitrakar ◽  
Sarah Cherian ◽  
Rekha Damle
2015 ◽  
Vol 35 (3) ◽  
Author(s):  
Chonticha Saisawang ◽  
Pornpan Sillapee ◽  
Kwanhathai Sinsirimongkol ◽  
Sukathida Ubol ◽  
Duncan R. Smith ◽  
...  

The protease role of alphavirus nsP2 is critical for virus replication as only the virus protease processes the viral non-structural polypeptide. We show chikungunya nsP2 protease possesses different substrate specificity to the canonical alphavirus nsP2 polyprotein cleavage specificity.


2013 ◽  
Vol 9 (4) ◽  
pp. e1003312 ◽  
Author(s):  
Pankaj Pal ◽  
Kimberly A. Dowd ◽  
James D. Brien ◽  
Melissa A. Edeling ◽  
Sergey Gorlatov ◽  
...  

1994 ◽  
Vol 375 (7) ◽  
pp. 471-480 ◽  
Author(s):  
Frank O. Gombert ◽  
William Werz ◽  
Michael Schlüter ◽  
Anja Bayer ◽  
Rolf G. Werner ◽  
...  

2021 ◽  
Author(s):  
Allison August ◽  
Husain Z. Attarwala ◽  
Sunny Himansu ◽  
Shiva Kalidindi ◽  
Sophia Lu ◽  
...  

AbstractChikungunya virus (CHIKV) infection causes acute disease characterized by fever, rash and arthralgia, which progresses to severe and chronic arthritis in up to 50% of patients. Moreover, CHIKV infection can be fatal in infants or immunocompromised individuals and has no approved therapy or prevention. This phase 1, first-in-human, randomized, placebo-controlled, proof-of-concept trial conducted from January 2019 to June 2020 evaluated the safety and pharmacology of mRNA-1944, a lipid nanoparticle-encapsulated messenger RNA encoding the heavy and light chains of a CHIKV-specific monoclonal neutralizing antibody, CHKV-24 (NCT03829384). The primary outcome was to evaluate the safety and tolerability of escalating doses of mRNA-1944 administered via intravenous infusion in healthy participants aged 18–50 years. The secondary objectives included determination of the pharmacokinetics of mRNA encoding for CHKV-24 immunoglobulin heavy and light chains and ionizable amino lipid component and the pharmacodynamics of mRNA-1944 as assessed by serum concentrations of mRNA encoding for CHKV-24 immunoglobulin G (IgG), plasma concentrations of ionizable amino lipid and serum concentrations of CHKV-24 IgG. Here we report the results of a prespecified interim analysis of 38 healthy participants who received intravenous single doses of mRNA-1944 or placebo at 0.1, 0.3 and 0.6 mg kg−1, or two weekly doses at 0.3 mg kg−1. At 12, 24 and 48 h after single infusions, dose-dependent levels of CHKV-24 IgG with neutralizing activity were observed at titers predicted to be therapeutically relevant concentrations (≥1 µg ml−1) across doses that persisted for ≥16 weeks at 0.3 and 0.6 mg kg−1 (mean t1/2 approximately 69 d). A second 0.3 mg kg−1 dose 1 week after the first increased CHKV-24 IgG levels 1.8-fold. Adverse effects were mild to moderate in severity, did not worsen with a second mRNA-1944 dose and none were serious. To our knowledge, mRNA-1944 is the first mRNA-encoded monoclonal antibody showing in vivo expression and detectable ex vivo neutralizing activity in a clinical trial and may offer a treatment option for CHIKV infection. Further evaluation of the potential therapeutic use of mRNA-1944 in clinical trials for the treatment of CHIKV infection is warranted.


2017 ◽  
Vol 9 (375) ◽  
pp. eaah3438 ◽  
Author(s):  
Jonathan J. Miner ◽  
Lindsey E. Cook ◽  
Jun P. Hong ◽  
Amber M. Smith ◽  
Justin M. Richner ◽  
...  

Virology ◽  
2014 ◽  
Vol 464-465 ◽  
pp. 111-117 ◽  
Author(s):  
Promsin Masrinoul ◽  
Orapim Puiprom ◽  
Atsushi Tanaka ◽  
Miwa Kuwahara ◽  
Panjaporn Chaichana ◽  
...  

2014 ◽  
Vol 199 ◽  
pp. 86-94 ◽  
Author(s):  
Soma Chattopadhyay ◽  
Abhishek Kumar ◽  
Prabhudutta Mamidi ◽  
Tapas Kumar Nayak ◽  
Indrani Das ◽  
...  

2020 ◽  
Vol 94 (19) ◽  
Author(s):  
Uranan Tumkosit ◽  
Uamporn Siripanyaphinyo ◽  
Naokazu Takeda ◽  
Motonori Tsuji ◽  
Yusuke Maeda ◽  
...  

ABSTRACT Chikungunya fever, a mosquito-borne disease manifested by fever, rash, myalgia, and arthralgia, is caused by chikungunya virus (CHIKV), which belongs to the genus Alphavirus of the family Togaviridae. Anti-CHIKV IgG from convalescent patients is known to directly neutralize CHIKV, and the state of immunity lasts throughout life. Here, we examined the epitope of a neutralizing mouse monoclonal antibody against CHIKV, CHE19, which inhibits viral fusion and release. In silico docking analysis showed that the epitope of CHE19 was localized in the viral E2 envelope and consisted of two separate segments, an N-linker and a β-ribbon connector, and that its bound Fab fragment on E2 overlapped the position that the E3 glycoprotein originally occupied. We showed that CHIKV-E2 is lost during the viral internalization and that CHE19 inhibits the elimination of CHIKV-E2. These findings suggested that CHE19 stabilizes the E2-E1 heterodimer instead of E3 and inhibits the protrusion of the E1 fusion loop and subsequent membrane fusion. In addition, the antigen-bound Fab fragment configuration showed that CHE19 connects to the CHIKV spikes existing on the two individual virions, leading us to conclude that the CHE19-CHIKV complex was responsible for the large virus aggregations. In our subsequent filtration experiments, large viral aggregations by CHE19 were trapped by a 0.45-μm filter. This virion-connecting characteristic of CHE19 could explain the inhibition of viral release from infected cells by the tethering effect of the virion itself. These findings provide clues toward the development of effective prophylactic and therapeutic monoclonal antibodies against the Alphavirus infection. IMPORTANCE Recent outbreaks of chikungunya fever have increased its clinical importance. Neither a specific antiviral drug nor a commercial vaccine for CHIKV infection are available. Here, we show a detailed model of the docking between the envelope glycoprotein of CHIKV and our unique anti-CHIKV-neutralizing monoclonal antibody (CHE19), which inhibits CHIKV membrane fusion and virion release from CHIKV-infected cells. Homology modeling of the neutralizing antibody CHE19 and protein-protein docking analysis of the CHIKV envelope glycoprotein and CHE19 suggested that CHE19 inhibits the viral membrane fusion by stabilizing the E2-E1 heterodimer and inhibits virion release by facilitating the formation of virus aggregation due to the connecting virions, and these predictions were confirmed by experiments. Sequence information of CHE19 and the CHIKV envelope glycoprotein and their docking model will contribute to future development of an effective prophylactic and therapeutic agent.


2017 ◽  
Vol 11 (6) ◽  
pp. e0005637 ◽  
Author(s):  
Rebecca Broeckel ◽  
Julie M. Fox ◽  
Nicole Haese ◽  
Craig N. Kreklywich ◽  
Soila Sukulpovi-Petty ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document